Article
Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
Clinical breast cancer - 1 Jun 2022
Walsh Elaine M, Mangini Neha, Fetting John, Armstrong Deborah, Chan Isaac S, Connolly Roisin M, Fiallos Katie, Lehman Jennifer, Nunes Raquel, Petry Dana, Reynolds Jeffrey, Shah Mirat, Smith Karen L, Visvanathan Kala, Lauring Josh, Park Ben H, Stearns Vered, Wolff Antonio C
Abstract excerpt
BACKGROUND: Poly-ADP ribose polymerase (PARP) inhibitors (PARPi) are active in patients with germline BRCA1/2 (gBRCA1/2)-mutated breast cancer, accounting for 5% to 10% of all breast cancers. Another 5% to 10% harbor somatic BRCA1/2 (sBRCA1/2) mutations or mutations in non-BRCA1/2, homologous recombination repair (HRR) genes but until recently, there were no data for the use of PARPi in these patients. This study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.